The role of liquid biopsy in the diagnosis of glioblastoma progression

The role of liquid biopsy in the diagnosis of glioblastoma progression

Автор: Ryabova A.I., Novikov V.A., Choynzonov E.L., Spirina L.V., Yunusova N.V., Ponomareva A.A., Tamkovich S.N., Gribova O.V.

Журнал: Сибирский онкологический журнал @siboncoj

Рубрика: Обзоры

Статья в выпуске: 3 т.21, 2022 года.

Бесплатный доступ

Purpose: to summarize available data on the diagnostic value of various circulating biomarkers for the detection of glioblastoma recurrence. material and methods. a literature search was conducted using pubmed exocarta and silVa databases. results. glioblastoma multiforme (gBm) is the most common glioma in adults with an unfavorable prognosis. treatment of tumor recurrence can improve the survival of patients. Neuroimaging is the standard method of diagnosing brain tumor recurrence. However, a neuroimaging method to clearly distinguish between pseudo progression and tumor progression has not been found to date. current molecular tumor profiling relies heavily on tissue resection or biopsy. tissue profiling has several disadvantages in the central nervous system’s tumors, including the challenge associated with invasive biopsy, the heterogeneous nature of many malignancies where a small biopsy can under represent the mutational profile. liquid biopsy is a promising method in diagnosing malignant tumors. Blood collection is a simple, minimally invasive procedure, but cerebrospinal fluid allows tumor markers to be detected more confidently. However, collection of cerebrospinal fluid is a complex and invasive procedure that can be accompanied by serious complications. conclusion. Biological fluid markers such as circulating tumor cells, extracellular vesicles, cell-free dNa and cell-free RNa allow for the detection of gmB, determination of molecular genetic features of cancer during response to therapy, and early detection of gBm recurrence.

Еще

Extracellular vesicles, cell-free dna, cell-free rna, circulating tumor cells, glioblastoma recurrence, tumor diagnostics

Короткий адрес: https://sciup.org/140295084

IDR: 140295084   |   DOI: 10.21294/1814-4861-2022-21-3-104-116

Список литературы The role of liquid biopsy in the diagnosis of glioblastoma progression

  • Ostrom Q.T., Cioffi G., Gittleman H., Patil N., Waite K., Kruchko C., Barnholtz-Sloan J.S. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 20122016. Neuro Oncol. 2019; 21(5):1-100. doi: 10.1093/neuonc/noz150.
  • ChinotO.L., Wick W., Mason W., HenrikssonR., SaranF., NishikawaR., Carpentier A.F., Hoang-Xuan K., Kavan P., Cernea D., Brandes A.A., Hilton M., Abrey L., Cloughesy T. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014; 370(8): 709-22. doi: 10.1056/NEJMoa1308345.
  • GilbertM.R., Dignam J.J., Armstrong T.S., Wefel J.S., BlumenthalD. T., Vogelbaum M.A., Colman H., Chakravarti A., Pugh S., Won M., Jeraj R., Brown P.D., Jaeckle K.A., SchiffD., Stieber V.W., Brachman D.G., Werner-WasikM., Tremont-LukatsI.W., SulmanE.P., AldapeK.D., Curran W.J. Jr., Mehta M.P. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014; 370(8): 699-708. doi: 10.1056/ NEJMoa1308573.
  • Stupp R., Taillibert S., Kanner A., Read W., Steinberg D., Lher-mitte B., Toms S., Idbaih A., Ahluwalia M.S., Fink K., Di Meco F., Lieber-man F., Zhu J.J., Stragliotto G., Tran D., Brem S., Hottinger A., Kirson E.D., Lavy-Shahaf G., Weinberg U., Kim C.Y., PaekS.H., Nicholas G., Bruna J., HirteH., WellerM., Palti Y., HegiM.E., Ram Z. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA. 2017; 318(23): 2306-16. doi: 10.1001/jama.2017.18718.
  • Louis D.N., Perry A., Reifenberger G., von Deimling A., Figarella-Branger D., Cavenee W.K., Ohgaki H., Wiestler O.D., Kleihues P., EllisonD.W. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131(6): 803-20. doi: 10.1007/s00401-016-1545-1.
  • Soffietti R., Franchino F., Magistrello M., Pellerino A., Rudà R. Perspectives of Personalized Chemotherapy of Gliomas Based on Molecular Tumor Profiling. Prog Neurol Surg. 2018; 31: 168-79. doi: 10.1159/000467378.
  • Weller M., Le Rhun E., Preusser M., Tonn J.C., Roth P. How we treat glioblastoma. ESMO Open. 2019; 4(2). doi: 10.1136/esmoo-pen-2019-000520.
  • Strauss S.B., Meng A., Ebani E.J., Chiang G.C. Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis. Radiol Clin North Am. 2019; 57(6): 1199-216. doi: 10.1016/j.rcl.2019.07.003.
  • Arevalo O.D., Soto C., Rabiei P., Kamali A., Ballester L.Y., Es-quenazi Y., Zhu J.J., Riascos R.F. Assessment of Glioblastoma Response in the Era of Bevacizumab: Longstanding and Emergent Challenges in the Imaging Evaluation of Pseudoresponse. Front Neurol. 2019; 10: 460. doi: 10.3389/fneur. 2019.00460.
  • Zikou A., Sioka C., Alexiou G.A., Fotopoulos A., Voulgaris S., Argyropoulou M.I. Radiation Necrosis, Pseudoprogression, Pseudor-esponse, and Tumor Recurrence: Imaging Challenges for the Evaluation of Treated Gliomas. Contrast Media Mol Imaging. 2018; 2018: 6828396. doi: 10.1155/2018/6828396.
  • Macarthur K.M., Kao G.D., Chandrasekaran S., Alonso-Basan-ta M., Chapman C., Lustig R.A., Wileyto E.P., Hahn S.M., Dorsey J.F. Detection of brain tumor cells in the peripheral blood by a telomerase promoter-based assay. Cancer Res. 2014; 74(8): 2152-9. doi: 10.1158/0008-5472.CAN-13-0813.
  • Gao F., Cui Y., Jiang H., Sui D., Wang Y., Jiang Z., Zhao J., Lin S. Circulating tumor cell is a common property of brain glioma and promotes the monitoring system. Oncotarget. 2016; 7(44): 71330-40. doi: 10.18632/ oncotarget.11114.
  • Mohammadi H., Shiue K., Grass G.D., Verma V., Engellandt K., Daubner D., Schackert G., Gondim M.J., Gondim D., Vortmeyer A.O., Kamer A.P., William J., Robinson T.J., Watson G., Yu H.H.M., Lauten-schlaeger T. Isocitrate dehydrogenase 1 mutant glioblastomas demonstrate a decreased rate of pseudoprogression: a multi-institutional experience. Neurooncol Pract. 2020; 7(2): 185-95. doi: 10.1093/nop/npz050.
  • SottorivaA., Spiteri I., Piccirillo S.G., Touloumis A., Collins V.P., Marioni J.C., Curtis C., Watts C., Tavaré S. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci USA. 2013; 110(10): 4009-14. doi: 10.1073/pnas.1219747110.
  • DraaismaK., ChatzipliA., TaphoornM., KerkhofM., Weyerbrock A., SansonM., HoebenA., Lukacova S., Lombardi G., Leenstra S., HanseM., Fleischeuer R., Watts C., McAbee J., Angelopoulos N., Gorlia T., Golfinopoulos V., Kros J.M., VerhaakR.G.W., Bours V., van den Bent M.J., McDermott U., Robe P.A., French P.J. Molecular Evolution of IDH WildType Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study. J Clin Oncol. 2020; 38(1): 81-99. doi: 10.1200/jc0.19.00367.
  • García-Romero N., Carrión-Navarro J., Esteban-Rubio S., Lázaro-IbáñezE., Peris-CeldaM., AlonsoM.M., Guzmán-De-Villoria J., Fernández-Carballal C., deMendivil A.O., García-Duque S., Escobedo-Lucea C., Prat-AcínR., Belda-Iniesta C., Ayuso-Sacido A. DNA sequences within glioma-derived extracellular vesicles can cross the intact blood-brain barrier and be detected in peripheral blood of patients. Oncotarget. 2017; 8(1): 1416-28. doi: 10.18632/oncotarget.13635.
  • Shankar G.M., Balaj L., Stott S.L., NahedB., Carter B.S. Liquid biopsy for brain tumors. Expert Rev Mol Diagn. 2017; 17(10): 943-7. doi: 10.1080/14737159.2017.1374854.
  • Müller Bark J., Kulasinghe A., Chua B., Day B. W., Punyadeera C. Circulating biomarkers in patients with glioblastoma. Br J Cancer. 2020; 122(3): 295-305. doi: 10.1038/s41416-019-0603-6.
  • Silantyev A.S., Falzone L., Libra M., Gurina O.I., Kardashova K.S., Nikolouzakis T.K., Nosyrev A.E., Sutton C.W., Mitsias P.D., Tsatsakis A. Current and Future Trends on Diagnosis and Prognosis of Glioblastoma: From Molecular Biology to Proteomics. Cells. 2019; 8(8): 863. doi: 10.3390/cells8080863.
  • Quddusi A., Shamim M.S. Serum biomarkers for glioblastoma multiforme. J Pak Med Assoc. 2019; 69(6): 913-4.
  • Figueroa J.M., Skog J., Akers J., Li H., Komotar R., Jensen R., Ringel F., Yang I., Kalkanis S., Thompson R., LoGuidice L., Berghoff E., Parsa A., Liau L., Curry W., Cahill D., Bettegowda C., Lang F.F., ChioccaE.A., Henson J., Kim R., BreakefieldX., Chen C., MesserK., Höchberg F., Carter B.S. Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients. Neuro Oncol. 2017; 19(11): 1494-1502. doi: 10.1093/neuonc/nox085.
  • Lee J.S., Melisko M.E., Magbanua M.J., Kablanian A.T., Scott J.H., Rugo H.S., Park J.W. Detection of cerebrospinal fluid tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer. Breast Cancer Res Treat. 2015; 154(2): 339-49. doi: 10.1007/ s10549-015-3610-1.
  • 23.MalaniR., FleisherM., Kumthekar P., LinX., OmuroA., GrovesM.D., Lin N. U., MeliskoM., Lassman A.B., Jeyapalan S., Seidman A., Skakodub A., BoireA., DeAngelisL.M., RosenblumM., Raizer J., PentsovaE. Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptome-ningeal metastases in patients with HER2 positive cancer. J Neurooncol. 2020; 148(3): 599-606. doi: 10.1007/s11060-020-03555-z.
  • Katz R.L., Zaidi T.M., Ni X. Liquid Biopsy: Recent Advances in the Detection of Circulating Tumor Cells and Their Clinical Applications. In: Bui MM, Pantanowitz L (eds). Modern Techniques in Cytopathology. Monogr Clin Cytol. Basel, Karger. 2020; 25: 43-66. doi: 10.1159/000455780.
  • Müller C., Holtschmidt J., Auer M., Heitzer E., Lamszus K., Schulte A., Matschke J., Langer-Freitag S., Gasch C., Stoupiec M., Mauermann O., Peine S., Glatzel M., Speicher M.R., Geigl J.B., Westphal M., Pantel K., Riethdorf S. Hematogenous dissemination of glioblastoma multiforme. Sci Transl Med. 2014; 6(247). doi: 10.1126/ scitranslmed.3009095.
  • Carvalho J.A.D.V., Barbosa C.C.L., Feher O., Maldaun M.V.C., Camargo V.P., MoraesF.Y., Marta G.N. Systemic dissemination of glioblastoma: literature review. Rev Assoc Med Bras (1992). 2019; 65(3): 460-8. doi: 10.1590/1806-9282.65.3.460.
  • Böhm C., Wassmann H., Paulus W. No evidence of tumour cells in blood of patients with glioma. Mol Pathol. 2003; 56(3): 187-9. doi: 10.1136/mp.56.3.187.
  • Sullivan J.P., Nahed B. V., MaddenM. W., Oliveira S.M., Springer S., Bhere D., Chi A.S., Wakimoto H., Rothenberg S.M., Sequist L.V., Kapur R., ShahK., IafrateA.J., Curry W.T., Loeffler J.S., Batchelor T.T., LouisD.N., TonerM., Maheswaran S., HaberD.A. Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discov. 2014; 4(11): 1299-309. doi: 10.1158/2159-8290.CD-14-0471.
  • Kolostova K., Pospisilova E., Pavlickova V., Bartos R., Sames M., Pawlak I., Bobek V. Next generation sequencing of glioblastoma circulating tumor cells: non-invasive solution for disease monitoring. Am J Transl Res. 2021; 13(5): 4489-99.
  • Hallal S., Ebrahimkhani S., Shivalingam B., Graeber M.B., Kaufman K.L., Buckland M.E. The emerging clinical potential of circulating extracellular vesicles for non-invasive glioma diagnosis and disease monitoring. Brain Tumor Pathol. 2019; 36(2): 29-39. doi: 10.1007/ s10014-019-00335-0.
  • Chen W.W., Balaj L., Liau L.M., Samuels M.L., Kotsopoulos S.K., Maguire C.A., Loguidice L., Soto H., Garrett M., Zhu L.D., Sivaraman S., Chen C., Wong E.T., Carter B.S., Hochberg F.H., Breakefield X.O., Skog J. BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles. Mol Ther Nucleic Acids. 2013; 2(7): 109. doi: 10.1038/ mtna.2013.28.
  • Lane R., Simon T., Vintu M., Solkin B., Koch B., Stewart N., Benstead-Hume G., Pearl F.M.G., Critchley G., Stebbing J., Giamas G. Cell-derived extracellular vesicles can be used as a biomarker reservoir for glioblastoma tumor subtyping. Commun Biol. 2019; 2: 315. doi: 10.1038/ s42003-019-0560-x.
  • Wang H., Jiang D., Li W., XiangX., Zhao J., Yu B., Wang C., He Z., Zhu L., Yang Y. Evaluation of serum extracellular vesicles as noninvasive diagnostic markers of glioma. Theranostics. 2019; 9(18): 5347-58.
  • Morishita M., Takahashi Y., Nishikawa M., Takakura Y. Phar-macokinetics of Exosomes-An Important Factor for Elucidating the Biological Roles of Exosomes and for the Development of Exosome-Based Therapeutics. J Pharm Sci. 2017; 106(9): 2265-9. doi: 10.1016/j. xphs.2017.02.030.
  • Tamkovich S.N., Yunusova N.V., Stakheeva M.N., Somov A.K., Frolova A.Y., Kirushina N.A., Afanasyev S.G., Grigoryeva A.E,. Laktio-novP.P., Kondakova I.V. Isolation and characterization of exosomes from blood plasma of breast cancer and colorectal cancer patients. Biomed Khim. 2017; 63(2):165-9. doi: 10.18097/PBMC20176302165.
  • Ciccocioppo F., Lanuti P., Marchisio M., Miscia S. Extracellular Vesicles Involvement in the Modulation of the Glioblastoma Environment. J Oncol. 2020; 2020: 3961735. doi: 10.1155/2020/3961735.
  • Yekula A., Yekula A., Muralidharan K., Kang K., Carter B.S., Balaj L. Extracellular Vesicles in Glioblastoma Tumor Microenvironment. Front Immunol. 2020; 10: 3137. doi: 10.3389/fimmu.2019.03137.
  • André-Grégoire G., Bidère N., Gavard J. Temozolomide affects Extracellular Vesicles Released by Glioblastoma Cells. Biochimie. 2018; 155: 11-5. doi: 10.1016/j.biochi.2018.02.007.
  • Osti D., Del Bene M., Rappa G., Santos M., Matafora V., Richi-chi C., Faletti S., Beznoussenko G.V., MironovA., BachiA., FornasariL., Bongetta D., Gaetani P., DiMeco F., Lorico A., Pelicci G. Clinical Significance of Extracellular Vesicles in Plasma from Glioblastoma Patients. Clin Cancer Res. 2019; 25(1): 266-76. doi: 10.1158/1078-0432.CCR-18-1941.
  • Evans S.M., Putt M., Yang X.Y., Lustig R.A., Martinez-Lage M., Williams D., Desai A., Wolf R., Brem S., Koch C.J. Initial evidence that blood-borne microvesicles are biomarkers for recurrence and survival in newly diagnosed glioblastoma patients. J Neurooncol. 2016; 127(2): 391-400. doi: 10.1007/s11060-015-2051-3.
  • Koch C.J., Lustig R.A., Yang X.Y., Jenkins W.T., WolfR.L., Martinez-Lage M., Desai A., Williams D., Evans S.M. Microvesicles as a Biomarker for Tumor Progression versus Treatment Effect in Radiation/ Temozolomide-Treated Glioblastoma Patients. Transl Oncol. 2014; 7(6): 752-8. doi: 10.1016/j.tranon.2014.10.004.
  • Shao H., Chung J., Balaj L., Charest A., Bigner D.D., Carter B.S., HochbergF.H., BreakefieldX.O., WeisslederR., LeeH. Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat Med. 2012; 18(12): 1835-40. doi: 10.1038/nm.2994.
  • Akers J.C., Ramakrishnan V., Kim R., Skog J., Nakano I., Pingle S., Kalinina J., Hua W., Kesari S., Mao Y., BreakefieldX.O., HochbergF.H., Van Meir E.G., Carter B.S., Chen C.C. MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): a platform for glioblastoma biomarker development. PLoS One. 2013; 8(10): 78115. doi: 10.1371/ journal.pone.0078115.
  • Ebrahimkhani S., Vafaee F., Hallal S., Wei H., Lee M.Y.T., Young P.E., SatgunaseelanL., BeadnallH., BarnettM.H., Shivalingam B., Suter C.M., BucklandM.E., Kaufman K.L. Deep sequencing of circulating exosomal microRNA allows non-invasive glioblastoma diagnosis. NPJ Precis Oncol. 2018; 2: 28. doi: 10.1038/s41698-018-0071-0.
  • Jafari D., Tiyuri A., Rezaei E., Moradi Y., Jafari R., Jokar Shoorijeh F., Barati M. Diagnostic accuracy of cerebrospinal fluid and serum-isolated extracellular vesicles for glioblastoma: a systematic review and meta-analysis. Expert Rev Mol Diagn. 2020; 20(11): 1075-85. doi: 10.1080/14737159.2020.1844006.
  • Santangelo A., Imbrucè P., Gardenghi B., Belli L., Agushi R., Tamanini A., Munari S., Bossi A.M., Scambi I., Benati D., Mariotti R., Di Gennaro G., Sbarbati A., Eccher A., Ricciardi G.K., Ciceri E.M., Sala F., Pinna G., Lippi G., Cabrini G., Dechecchi M.C. A microRNA signature from serum exosomes of patients with glioma as complementary diagnostic biomarker. J Neurooncol. 2018; 136(1): 51-62. doi: 10.1007/ s11060-017-2639-x.
  • Lan F., Qing Q., Pan Q., Hu M., Yu H., Yue X. Serum exosomal miR-301a as a potential diagnostic and prognostic biomarker for human glioma. Cell Oncol (Dordr). 2018; 41(1): 25-33. doi: 10.1007/s13402-017-0355-3.
  • Lan F., Yue X., Xia T. Exosomal microRNA-210 is a potentially non-invasive biomarker for the diagnosis and prognosis of glioma. Oncol Lett. 2020; 19(3): 1967-74. doi: 10.3892/ol.2020.11249.
  • Galbo P.M. Jr., Ciesielski M.J., Figel S., Maguire O., Qiu J., Wiltsie L., Minderman H., Fenstermaker R.A. Circulating CD9+/GFAP+/ survivin+ exosomes in malignant glioma patients following survivin vaccination. Oncotarget. 2017; 8(70): 114722-35. doi: 10.18632/onco-target.21773.
  • Lv S., Dai C., Liu Y., Shi R., Tang Z., Han M., Bian R., Sun B., Wang R. Retraction Note to: The Impact of Survivin on Prognosis and Clinicopathology of Glioma Patients: A Systematic Meta-Analysis. Mol Neurobiol. 2017; 54(3): 2376. doi: 10.1007/s12035-017-0402-0.
  • Brennan K., Martin K., FitzGerald S.P., O'Sullivan J., Wu Y., Blanco A., Richardson C., Mc Gee M.M. A comparison of methods for the isolation and separation of extracellular vesicles from protein and lipid particles in human serum. Sci Rep. 2020. doi: https://doi.org/10.1038/ s41598-020-57497-7.
  • Tamkovich S., Bryzgunova O. Protease Activity and CellFree DNA in Blood Plasma of Healthy Donors and Breast Cancer Patients. J Immunoassay Immunochem. 2016; 37(2): 141-53. doi: 10.1080/15321819.2015.1069745.
  • Bryzgunova O.E., Tamkovich S.N., CherepanovaA.V., Yarmosh-chukS.V., Permyakova V.I., Anykeeva O.Y., LaktionovP.P. Redistribution of Free- and Cell-Surface-Bound DNA in Blood of Benign and Malignant Prostate Tumor Patients. Acta Naturae. 2015; 7(2): 115-8.
  • Bagley S.J., Nabavizadeh S.A., Mays J.J., Till J.E., Ware J.B., Levy S., Sarchiapone W., Hussain J., Prior T., Guiry S., Christensen T., Yee S.S., NasrallahM.P., Morrissette J.J.D., Binder Z.A., O'RourkeD.M., Cucchiara A.J., Brem S., Desai A.S., Carpenter E.L. Clinical Utility of Plasma Cell-Free DNA in Adult Patients with Newly Diagnosed Glioblastoma: A Pilot Prospective Study. Clin Cancer Res. 2020; 26(2): 397-407. doi: 10.1158/1078-0432.CCR-19-2533.
  • N0r0xe D.S., 0strup O., Yde C.W., Ahlborn L.B., Nielsen F.C., Michaelsen S.R., Larsen V.A., Skj0th-Rasmussen J., Brennum J., HamerlikP., Poulsen H.S., Lassen U. Cell-free DNA in newly diagnosed patients with glioblastoma - a clinical prospective feasibility study. Oncotarget. 2019; 10(43): 4397-4406. doi: 10.18632/oncotarget.27030.
  • Duvvuri B., Lood C. Cell-Free DNA as a Biomarker in Autoimmune Rheumatic Diseases. Front Immunol. 2019; 10: 502. doi: 10.3389/ fimmu.2019.00502.
  • Hou Y.Q., Liang D.Y., Lou X.L., Zhang M., Zhang Z.H., Zhang L.R. Branched DNA-based Alu quantitative assay for cell-free plasma DNA levels in patients with sepsis or systemic inflammatory response syndrome. J Crit Care. 2016; 31(1): 90-5. doi: 10.1016/j.jcrc.2015.10.013.
  • Jing R., Cui M., Wang H., Ju S. Cell-free DNA: characteristics, detection and its applications in myocardial infarction. Curr Pharm Des. 2013; 19(28): 5135-45. doi: 10.2174/1381612811319280012.
  • Balana C., Ramirez J.L., TaronM., Roussos Y., Ariza A., BallesterR., Sarries C., Mendez P., Sanchez J.J., Rosell R. O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cispla-tin in glioblastoma multiforme. Clin Cancer Res. 2003; 9(4): 1461-8.
  • Weaver K.D., Grossman S.A., Herman J.G. Methylated tumor-specific DNA as a plasma biomarker in patients with glioma. Cancer Invest. 2006; 24(1): 35-40. doi: 10.1080/07357900500449546.
  • Majchrzak-Celinska A., Paluszczak J., Kleszcz R., Magiera M., Barciszewska A.M., Nowak S., Baer-Dubowska W. Detection of MGMT, RASSF1A, p15INK4B, and p14ARF promoter methylation in circulating tumor-derived DNA of central nervous system cancer patients. J Appl Genet. 2013; 54(3): 335-44. doi: 10.1007/s13353-013-0149-x.
  • Lavon I., Refael M., Zelikovitch B., Shalom E., Siegal T. Serum DNA can define tumor-specific genetic and epigenetic markers in glio-mas of various grades. Neuro Oncol. 2010; 12(2): 173-80. doi: 10.1093/ neuonc/nop041.
  • BoisselierB., GallegoPerez-Larraya J., RossettoM., LabussiereM., CiccarinoP., Marie Y., Delattre J.Y., SansonM. Detection of IDH1 mutation in the plasma of patients with glioma. Neurology. 2012; 79(16): 1693-8. doi: 10.1212/WNL.0b013e31826e9b0a.
  • SalkeniM.A., Zarzour A., Ansay T.Y., McPhersonC.M., WarnickR.E., Rixe O., Bahassi elM. Detection of EGFRvIII mutant DNA in the peripheral blood of brain tumor patients. J Neurooncol. 2013; 115(1): 27-35. doi: 10.1007/s11060-013-1209-0.
  • Bettegowda C., Sausen M., Leary R.J., Kinde I., Wang Y., Agrawal N., BartlettB.R., WangH., LuberB., AlaniR.M., AntonarakisE.S., AzadN.S., Bardelli A., Brem H., Cameron J.L., Lee C.C., Fecher L.A., Gallia G.L., Gibbs P., Le D., Giuntoli R.L., Goggins M., Hogarty M.D., Holdhoff M., Hong S.M., Jiao Y., Juhl H.H., Kim J.J., Siravegna G., Laheru D.A., Lauricella C., Lim M., Lipson E.J., Marie S.K., Netto G.J., Oliner K.S., OliviA., OlssonL., Riggins G.J., Sartore-BianchiA., SchmidtK., Shih l.M., Oba-Shinjo S.M., Siena S., Theodorescu D., Tie J., Harkins T.T., Veronese S., Wang T.L., Weingart J.D., Wolfgang C.L., Wood L.D., Xing D., HrubanR.H., Wu J., AllenP.J., SchmidtC.M., ChotiM.A., Velculescu V.E., KinzlerK.W., Vogelstein B., Papadopoulos N., Diaz L.A. Jr. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014; 6(224). doi: 10.1126/scitranslmed.3007094.
  • Schwaederle M., Husain H., Fanta P.T., Piccioni D.E., Kesari S., Schwab R.B., Banks K.C., Lanman R.B., Talasaz A., Parker B.A., Kurzrock R. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. Oncotarget. 2016; 7(9): 9707-17. doi: 10.18632/oncotarget.7110.
  • Piccioni D.E., Achrol A.S., Kiedrowski L.A., Banks K.C., Boucher N., Barkhoudarian G., Kelly D.F., Juarez T., Lanman R.B., Raymond V.M., Nguyen M., Truong J.D., Heng A., Gill J., Saria M., Pingle S.C., Kesari S. Analysis of cell-free circulating tumor DNA in 419 patients with gliob-lastoma and other primary brain tumors. CNS Oncol. 2019; 8(2). doi: 10.2217/cns-2018-0015.
  • Ahmed K.I., Govardhan H.B., Roy M., Naveen T., Siddanna P., Sridhar P., Suma M.N., Nelson N. Cell-free circulating tumor DNA in patients with high-grade glioma as diagnostic biomarker - A guide to future directive. Indian J Cancer. 2019; 56(1): 65-9. doi: 10.4103/ijc. IJC_551_17.
  • Wang Z., Jiang W., Wang Y., Guo Y., Cong Z., Du F., Song B. MGMT promoter methylation in serum and cerebrospinal fluid as a tumor-specific biomarker of glioma. Biomed Rep. 3(4) (2015), 543-548.
  • Wang Y., Springer S., Zhang M., McMahon K.W., Kinde I., Dob-byn L., Ptak J., Brem H., Chaichana K., Gallia G.L., Gokaslan Z.L., Groves M.L., Jallo G.I., Lim M., Olivi A., Quinones-Hinojosa A., Riga-montiD., Riggins G.J., SciubbaD.M., Weingart J.D., Wolinsky J.P., YeX., Oba-Shinjo S.M., Marie S.K., Holdhoff M., Agrawal N., Diaz L.A. Jr., Papadopoulos N., Kinzler K.W., Vogelstein B., Bettegowda C. Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. Proc Natl Acad Sci USA. 2015; 112(31): 9704-9. doi: 10.1073/pnas.1511694112.
  • Osei E., Walters P., Masella O., Tennant Q., FishwickA., Dadzie E., Bhangu A., Darko J. A review of predictive, prognostic and diagnostic biomarkers for brain tumours: Towards personalised and targeted cancer therapy. J Radiother Pract. 2019; 1-16.
  • Rhodes C.H., Honsinger C., Sorenson G.D. PCR-detection of tumor-derived p53 DNA in cerebrospinal fluid. Am J Clin Pathol. 1995; 103(4): 404-8. doi: 10.1093/ajcp/103.4.404.
  • De Mattos-Arruda L., Mayor R., Ng C.K.Y., Weigelt B., Martínez-Ricarte F., Torrejon D., Oliveira M., Arias A., Raventos C., Tang J., Guerini-Rocco E., Martínez-Sáez E., Lois S., Marín O., de la Cruz X., Piscuoglio S., Towers R., Vivancos A., Peg V., Ramon y Cajal S., Carles J., Rodon J., González-Cao M., Tabernero J., Felip E., Sahuquillo J., Berger M.F., Cortes J., Reis-Filho J.S., Seoane J. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun. 2015; 6: 8839. doi: 10.1038/ ncomms9839.
  • Miller A.M., Shah R.H., Pentsova E.I., Pourmaleki M., Briggs S., Distefano N., Zheng Y., Skakodub A., Mehta S.A., Campos C., Hsieh W.Y., Selcuklu S.D., Ling L., Meng F., Jing X., Samoila A., Bale T.A., Tsui D.W.Y., Grommes C., Viale A., Souweidane M.M., Tabar V., Brennan C.W., Reiner A.S., Rosenblum M., Panageas K.S., DeAngelis L.M., Young R.J., BergerM.F., Mellinghoff I.K. Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. Nature. 2019; 565(7741): 654-8. doi: 10.1038/s41586-019-0882-3.
  • Day G.S., Rappai T., Sathyan S., Morris J.C. Deciphering the factors that influence participation in studies requiring serial lumbar punctures. Alzheimers Dement (Amst). 2020; 12(1). doi: 10.1002/dad2.12003.
  • Zhang Y., Cruickshanks N., Pahuski M., Yuan F., Dutta A., Schiff D., Purow B., Abounader R. Noncoding RNAs in Glioblastoma. In: De Vleeschouwer S, editor. Glioblastoma [Internet]. Brisbane (AU): Codon Publications; 2017.
  • Zorofchian S., IqbalF., RaoM., Aung P.P., Esquenazi Y., Ballester L.Y. Circulating tumour DNA, microRNA and metabolites in cerebrospinal fluid as biomarkers for central nervous system malignancies. J Clin Pathol. 2019; 72(4): 271-80. doi: 10.1136/jclinpath-2018-205414.
  • DuanX., Liu D., Wang Y., Chen Z. Circular RNAhsa_circ_0074362 Promotes Glioma Cell Proliferation, Migration, and Invasion by Attenuating the Inhibition of miR-1236-3p on HOXB7 Expression. DNA Cell Biol. 2018; 37(11): 917-24. doi: 10.1089/dna.2018.4311.
  • Song X., Zhang N., Han P., Moon B.S., Lai R.K., Wang K., Lu W. Circular RNA profile in gliomas revealed by identification tool UROBORUS. Nucleic Acids Res. 2016; 44(9). doi: 10.1093/nar/gkw075.
  • 80.BarbagalloD., CaponnettoA., CirnigliaroM., BrexD., BarbagalloC., D'Angeli F., Morrone A., Caltabiano R., Barbagallo G.M., Ragusa M., DiPietro C., Hansen T.B., PurrelloM. CircSMARCA5 Inhibits Migration of Glioblastoma Multiforme Cells by Regulating a Molecular Axis Involving Splicing Factors SRSF1/SRSF3/PTB. Int J Mol Sci. 2018; 19(2): 480. doi: 10.3390/ijms19020480.
  • Wang Y., SuiX., Zhao H., Cong L., Li Y., Xin T., GuoM., Hao W. Decreased circular RNA hsa_circ_0001649 predicts unfavorable prognosis in glioma and exerts oncogenic properties in vitro and in vivo. Gene. 2018; 676: 117-22. doi: 10.1016/j.gene.2018.07.037.
  • Barbagallo D., CaponnettoA., BrexD., Mirabella F., Barbagallo C., Lauretta G., Morrone A., Certo F., Broggi G., Caltabiano R., Barbagallo G.M., Spina-Purrello V., Ragusa M., Di Pietro C., Hansen T.B., Purrello M. CircSMARCA5 Regulates VEGFA mRNA Splicing and Angiogenesis in Glioblastoma Multiforme Through the Binding of SRSF1. Cancers (Basel). 2019; 11(2): 194. doi: 10.3390/cancers11020194.
  • Jin P., Huang Y., Zhu P., Zou Y., Shao T., Wang O. CircRNA cir-cHIPK3 serves as a prognostic marker to promote glioma progression by regulating miR-654/IGF2BP3 signaling. Biochem Biophys Res Commun. 2018; 503(3): 1570-4. doi: 10.1016/j.bbrc.2018.07.081.
  • Zhang M., Huang N., Yang X., Luo J., Yan S., Xiao F., Chen W., Gao X., Zhao K., Zhou H., Li Z., Ming L., Xie B., Zhang N. A novel protein encoded by the circular form of the SHPRH gene suppresses glioma tumorigenesis. Oncogene. 2018; 37(13): 1805-14. doi: 10.1038/ s41388-017-0019-9.
  • Yang M., Li G., Fan L., Zhang G., Xu J., Zhang J. Circular RNA circ_0034642 elevates BATF3 expression and promotes cell proliferation and invasion through miR-1205 in glioma. Biochem Biophys Res Commun. 2019; 508(3): 980-5. doi: 10.1016/j.bbrc.2018.12.052.
  • LeiB., Huang Y., Zhou Z., Zhao Y., Thapa A.J., Li W., Cai W., Deng Y. Circular RNA hsa_circ_0076248 promotes oncogenesis of glioma by sponging miR-181a to modulate SIRT1 expression. J Cell Biochem. 2019; 120(4): 6698-6708. doi: 10.1002/jcb.27966.
  • Ding C., Yi X., Wu X., Bu X., Wang^ D., Wu Z., Zhang G., Gu J., Kang D. Exosome-mediated transfer of circRNA CircNFIX enhances temozolomide resistance in glioma. Cancer Lett. 2020; 479: 1-12. doi: 10.1016/j.canlet.2020.03.002.
  • DeOcesano-Pereira C., Machado R.A.C., Chudzinski-TavassiA.M., Sogayar M.C. Emerging Roles and Potential Applications of Non-Coding RNAs in Glioblastoma. Int J Mol Sci. 2020; 21(7): 2611. doi: 10.3390/ ijms21072611.
  • Chen W., Xu X.K., Li J.L., Kong K.K., Li H., Chen C., He J., Wang F., Li P., Ge X.S., Li F.C. MALAT1 is a prognostic factor in glioblas-toma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression. Oncotarget. 2017; 8(14): 22783-99. doi: 10.18632/oncotarget.15199.
  • 90.Mazor G., LevinL., Picard D., Ahmadov U., CarénH., Borkhardt A., Reifenberger G., Leprivier G., Remke M., Rotblat B. The lncRNA TP73-AS1 is linked to aggressiveness in glioblastoma and promotes temozolo-mide resistance in glioblastoma cancer stem cells. Cell Death Dis. 2019; 10(3): 246. doi: 10.1038/s41419-019-1477-5.
  • Liu Q., Qi C., Li G., Su W. Prediction of the Outcome for Patients with Glioblastoma with lncRNA Expression Profiles. Biomed Res Int. 2019. https://doi.org/10.1155/2019/5076467.
  • Wang Q., Li P., Li A., Jiang W., Wang H., Wang J., Xie K. Plasma specific miRNAs as predictive biomarkers for diagnosis and prognosis of glioma. J Exp Clin Cancer Res. 2012; 31(1): 97. doi: 10.1186/17569966-31-97.
  • Teplyuk N.M., Mollenhauer B., Gabriely G., Giese A., Kim E., Smolsky M., KimR.Y., SariaM.G., Pastorino S., Kesari S., Krichevsky A.M. MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. Neuro Oncol. 2012; 14(6): 689-700. doi: 10.1093/neuonc/nos074.
  • Roth P., Wischhusen J., Happold C., Chandran P.A., Hofer S., Eisele G., WellerM., Keller A. A specific miRNA signature in the peripheral blood of glioblastoma patients. J Neurochem. 2011; 118(3): 449-57. doi: 10.1111/j.1471-4159.2011.07307.x.
  • ManterolaL., GuruceagaE., GállegoPérez-Larraya J., González-HuarrizM., Jauregui P., Tejada S., Diez-Valle R., Segura V., SamprónN., Barrena C., Ruiz I., Agirre A., Ayuso A., Rodríguez J., González A., Xipell E., Matheu A., López deMunain A., Tuñón T., Zazpe I., García-Foncillas J., Paris S., Delattre J.Y., Alonso M.M. A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool. Neuro Oncol. 2014; 16(4): 520-7. doi: 10.1093/neuonc/not218.
  • Zhang Y., Ta W.W., Sun P.F., Meng Y.F., Zhao C.Z. Diagnostic and prognostic significance of serum miR-145-5p expression in glioblastoma. Int J Clin Exp Pathol. 2019; 12(7): 2536-43.
  • Srinivasan S., Patric I.R., Somasundaram K. A ten-microRNA expression signature predicts survival in glioblastoma. PLoS One. 2011; 6(3). doi: 10.1371/journal.pone.0017438.
  • Xiao Y., ZhangL., Song Z., Guo C., Zhu J., Li Z., Zhu S. Potential Diagnostic and Prognostic Value of Plasma Circulating MicroRNA-182 in Human Glioma. Med Sci Monit. 2016; 22: 855-62. doi: 10.12659/ msm.897164.
  • Zhao H., Shen J., Hodges T.R., Song^ R., Fuller G.N., Heimber-ger A.B. Serum microRNA profiling in patients with glioblastoma: a survival analysis. Mol Cancer. 2017; 16(1): 59. doi: 10.1186/s12943-017-0628-5.
  • Wang Z.Q., Zhang M.Y., Deng M.L., Weng N.Q., Wang H.Y., Wu S.X. Low serum level of miR-485-3p predicts poor survival in patients with glioblastoma. PLoS One. 2017; 12(9). doi: 10.1371/journal. pone.0184969.
  • Shi L., Zhang S., Feng K., Wu F., Wan Y., Wang Z., Zhang J., Wang Y., Yan W., Fu Z., You Y. MicroRNA-125b-2 confers human gliob-lastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis. Int J Oncol. 2012; 40(1): 119-29. doi: 10.3892/ ijo.2011.1179.
  • Huang B.S., Luo Q.Z., Han Y., Huang D., Tang Q.P., Wu L.X. MiR-223/PAX6 Axis Regulates Glioblastoma Stem Cell Proliferation and the Chemo Resistance to TMZ via Regulating PI3K/Akt Pathway. J Cell Biochem. 2017; 118(10): 3452-61. doi: 10.1002/jcb.26003.
  • GwakH.S., Kim T.H., Jo G.H., Kim Y.J., KwakH.J., Kim J.H., Yin J., Yoo H., Lee S.H., Park J.B. Silencing of microRNA-21 confers radio-sensitivity through inhibition of the PI3K/AKT pathway and enhancing autophagy in malignant glioma cell lines. PLoS One. 2012; 7(10). doi: 10.1371/journal.pone.0047449.
  • Sun J., Ye L., Wang C., Li N., Wang D., Li X. MicroRNA-128 increases glioma cell radio-sensitivity by suppressing senescent evasion through oncogene Bmi-1. Int J Clin Exp Pathol. 2018; 11(3): 1423-30.
  • YueX., LanF., Xia T. Hypoxic Glioma Cell-Secreted Exosomal miR-301a Activates Wnt/ß-catenin Signaling and Promotes Radiation Resistance by Targeting TCEAL7. Mol Ther. 2019; 27(11): 1939-49. doi: 10.1016/j.ymthe.2019.07.011.
  • Zhang^ Y., Ta W.W., Sun P.F., Meng Y.F., Zhao C.Z. Diagnostic and prognostic significance of serum miR-145-5p expression in glioblastoma. Int J Clin Exp Pathol. 2019; 12(7): 2536-43.
  • Zhou Q., Liu J., Quan J., Liu W, Tan H., Li W. MicroRNAs as potential biomarkers for the diagnosis of glioma: A systematic review and meta-analysis. Cancer Sci. 2018; 109(9): 2651-9. doi: 10.1111/ cas.13714.
  • Yue X., Lan F., Hu M., Pan Q., Wang Q., Wang J. Downregula-tion of serum microRNA-205 as a potential diagnostic and prognostic biomarker for human glioma. J Neurosurg. 2016; 124(1): 122-8. doi: 10.3171/2015.1.JNS141577.
  • Yang C, Wang C, Chen X., Chen S, Zhang Y, Zhi F, Wang J., Li L., Zhou X., Li N., Pan H., Zhang J., Zen K., Zhang C.Y., Zhang C. Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas. Int J Cancer. 2013; 132(1): 116-27. doi: 10.1002/ ijc.27657.
  • ShaoN., Wang L., Xue L., WangR., Lan Q. Plasma miR-454-3p as a potential prognostic indicator in human glioma. Neurol Sci. 2015; 36(2): 309-13. doi: 10.1007/s10072-014-1938-7.
  • Sun J., Liao K., Wu X., Huang J., Zhang S., Lu X. Serum micro-RNA-128 as a biomarker for diagnosis of glioma. Int J Clin Exp Med. 2015; 8(1): 456-63.
  • TangH., Liu Q., LiuX., YeF., XieX., XieX., WuM. Plasma miR-185 as a predictive biomarker for prognosis of malignant glioma. J Cancer Res Ther. 2015; 11(3): 630-4. doi: 10.4103/0973-1482.146121.
  • ParvizHamidiM., Haddad G., Ostadrahimi S., Ostadrahimi N., Sadeghi S., Fayaz S., Fard-Esfahani P. Circulating miR-26a and miR-21 as biomarkers for glioblastoma multiform. Biotechnol Appl Biochem. 2019; 66(2): 261-5. doi: 10.1002/bab.1707.
  • Wang J., Che F., Zhang J., Zhang M., Xiao S., Liu Y, Zhou L., Su Q., You C., Lu Y., Heng X. Diagnostic and Prognostic Potential of Serum Cell-Free microRNA-214 in Glioma. World Neurosurg. 2019; 125: 1217-25. doi: 10.1016/j.wneu.2019.02.009.
  • Akers J.C., Hua W., Li H., Ramakrishnan V., Yang Z., Quan K., Zhu W., Li J., Figueroa J., Hirshman B.R., Miller B., Piccioni D., Ringel F., Komotar R., Messer K., Galasko D.R., Hochberg F., Mao Y., Carter B.S., Chen C.C. A cerebrospinal fluid microRNA signature as biomarker for glioblastoma. Oncotarget. 2017; 8(40): 68769-79. doi: 10.18632/onco-target.18332.
Еще
Статья научная
SciUp 2024 © 2024 ©